Columbia Asset Management owns $8.57 million in Johnson & Johnson (NYSE:JNJ)

VaselineSeptember 7, 2024

0 4 minutes read

Columbia Asset Management boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.0% in the second quarter, HoldingsChannel.com reports. The firm owned 58,655 shares of the company’s stock after acquiring an additional 600 shares during the quarter. Johnson & Johnson makes up about 1.6% of Columbia Asset Management’s holdings, making the stock its 13th largest holding. Columbia Asset Management’s holdings in Johnson & Johnson were worth $8,573,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have recently made changes to their positions in the business. Citizens & Northern Corp boosted its holdings in Johnson & Johnson by 3.5% in the second quarter. Citizens & Northern Corp now owns 1,884 shares of the company’s stock worth $275,000 after purchasing an additional 63 shares during the period. Carolinas Wealth Consulting LLC raised its holdings in Johnson & Johnson by 0.4% in the fourth quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the company’s stock worth $2,643,000 after buying an additional 64 shares during the period. Epic Trust Investment Advisors LLC boosted its holdings in Johnson & Johnson by 3.6% in the second quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company’s stock worth $268,000 after purchasing an additional 64 shares during the period. Verity Asset Management Inc. grew its holdings in Johnson & Johnson by 2.0% in the fourth quarter. Verity Asset Management Inc. now owns 3,268 shares of the company’s stock worth $512,000 after buying an additional 65 shares during the period. Finally, Outfitter Financial LLC boosted its holdings in Johnson & Johnson by 0.4% in the second quarter. Outfitter Financial LLC now owns 16,632 shares of the company’s stock worth $2,431,000 after purchasing an additional 65 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s shares.

Johnson & Johnson price performance

JNJ opened at $164.41 on Friday. The firm has a 50-day moving average price of $157.57 and a 200-day moving average price of $153.83. The company has a market cap of $395.68 billion, a price-to-earnings ratio of 10.25, a PEG ratio of 2.73 and a beta of 0.52. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a quick ratio of 0.85, a current ratio of 1.07, and a debt-to-equity ratio of 0.44.

Want more great investment ideas?

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s revenue for the quarter was up 4.3% year-over-year. In the same quarter last year, the company earned $2.80 per share. equities analysts expect that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson announces dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, August 27th. This represents an annualized dividend of $4.96 and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insider work at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The sale was disclosed in a filing with the SEC, which is available via this hyperlink. 0.16% of shares are owned by corporate insiders.

Analyst upgrades and downgrades

A number of equities research analysts have commented on the shares. Goldman Sachs Group cut their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Tuesday. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $160.00 to $150.00 in a research note on Tuesday, July 23. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Moderate Buy” and a consensus price target of $173.21, according to MarketBeat.

Check out our latest analysis of JNJ

Johnson & Johnson profile

(Free report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.